Anti Neutrophil Cytoplasmic Autoantibody Anca Associated Vasculitis Granulomatosis With Polyangiitis And Microscopic Polyangiitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for anti neutrophil cytoplasmic autoantibody anca associated vasculitis granulomatosis with polyangiitis and microscopic polyangiitis . 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
4
Active US patents
35/100
Avg vulnerability
$400M
Annual revenue covered

Originators in Anti Neutrophil Cytoplasmic Autoantibody Anca Associated Vasculitis Granulomatosis With Polyangiitis And Microscopic Polyangiitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Chemocentryx 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating anti neutrophil cytoplasmic autoantibody anca associated vasculitis granulomatosis with polyangiitis and microscopic polyangiitis . Each bar = one year. Y-axis scaled to peak year (2 patents).

1
31
1
34
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tavneos
AVACOPAN
 Chemocentryx 4 35 $400M 2031-02-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11603356 Tavneos method of use 70 2039-11-27
11951214 Tavneos formulation 55 2039-11-27
8445515 Tavneos composition of matter 10 2031-02-03
8906938 Tavneos composition of matter 4 2034-01-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8906938 Tavneos composition of matter 4 2034-01-06
8445515 Tavneos composition of matter 10 2031-02-03
11951214 Tavneos formulation 55 2039-11-27
11603356 Tavneos method of use 70 2039-11-27

Related